International Workshop on Acute Leukemias (iwAL) 2021

28 – 30 April 2021

 

The Virtual iwAL workshop will be held between the 28th and 30th of April 2021. The program will focus on important questions in the field of research and clinical advances in ALL and AML as well as related hematological malignancies, showcasing stimulating and insightful content, as well as live interactive debate and panel sessions.

Apply for registration for iwAL here

This event is for hematologists, researchers, nurses, and allied medical professionals only. Please apply for registration by filling in the form and confirming your details. We will review your application and confirm your registration on submission. By applying, you confirm that your details are correct and that the organizer can communicate with you regarding this event.

Agenda (all times EST)

 

Wednesday 28th April 2021

10:00am EST Welcome Day 1: Dieter Hoelzer/Daniel DeAngelo

10.00-10.50 Session 1: Advances in T-ALL | Chairs: Jan Cools & Daniel DeAngelo

  • Update in T-ALL biology: Jan Cools
  • Prognostic impact of T-ALL subtype: Jonathan Bond
  • CAR T-cells for T-ALL?: He Huang
  • COG AALL0434 in newly diagnosed T-cell ALL: Stuart Winter 

Panel Discussion

10.50-11.50 Session 2: B-ALL | Chairs: Charles Mullighan & Robin Foa

  • Scientific update in B-ALL: Charles Mullighan
  • Blinatumomab in frontline pediatric ALL: Patrick Brown
  • Venetoclax plus navitoclax for ALL; Jeffrey Rubnitz
  • Reducing T-cell exhaustion with CD19/CD3 BiTEs: Nora Zieger

Panel Discussion

11:50-12:30 Session 3: MRD and diagnostics | Chairs: Sabina Chiaretti & Gianni Cazzaniga

  • Stratifying risk with MRD in ALL: Mignon Loh
  • MRD in infant ALL: Janine Stutterheim
  • MRD; which method and which sensitivity required?: Monika Bruggeman

Panel Discussion

12:30-13:10 Session 4: Immunotherapies| Chairs: Robin Foa & Daniel DeAngelo

  • R/R ALL: Blina or Ino first? Which combinations?
    • Inotuzumab: Elias Jabbour
    • Blinatumomab: Nicola Gokbucket

Panel Discussion

13:10-13:45 Session 5: CAR T-cell therapy in ALL | Chairs: Dieter Hoelzer & Sabina Chiaretti

  • Allografting for adults with ALL: our direction of travel: David Marks
  • Managing toxicities in CAR T-cell ALL patients: Jordan Gauthier
  • CAR T-cell therapy followed by transplant in children/YAs: Daniel Lee
  • A Feasibility and Safety Study of a Novel CD19-Directed Synthetic T-Cell Receptor and Antigen Receptor (STAR) T-Cell Therapy for Refractory and Relapsed B-ALL: Peggy Lu

Panel Discussion

End Day 1, Conclusions & Wrap up

Thursday 29th April 2021

10:00am EST Welcome and Introductions: Richard Stone and Mark Levis

10:00-10:50 Session 6: Advances in AML biology | Chairs: Marina Konopleva & Ravi Majeti

  • Single cell genomics and AML: Koichi Takahashi
  • Epigenomics in AML: Mark Dawson
  • Stem cells in human AML: Ravi Majeti
  • CHIP: updates and future directions: Liran Shlush

Panel Discussion

10:50-11:40 Session 7: Controversies in AML | Chairs: Richard Stone & Andrew Wei

  • 7+3 or VEN-AZA for complex karyotype AML
    • 7+3: Stephane De Botton
    • HMA-based: Daniel Pollyea

Panel Discussion

  • Is it safe to delay the initiation of induction?
    • Yes: Mark Levis
    • No: Gunnar Juliusson

Panel Discussion

11:40-12:40 Session 8: ASCT and post-ASCT maintenance approaches | Chairs: Charles Craddock & Sergio Giralt

  • Graft-versus-leukemia biology: Paresh Vyas
  • MRD and AML: Christopher Hourigan
  • UK Impact transplant trials: Charles Craddock
  • Optimizing the conditioning regimen in AML: Alessandro Rambaldi
  • Post-transplant maintenance therapy – where are we?: Victoria Potter
  • Novel immunotherapeutic strategies post-BMT: John DiPersio

Panel Discussion

12:40-13:40 Session 9: MDS new data/novel therapies | Chairs: Amer Zeidan & Guillermo Garcia-Manero

  • Venetoclax and immune checkpoint blockade in MDS: Amer Zeidan
  • Imetelstat and roxadustat in MDS: Valeria Santini
  • APR-246 and magrolimab in MDS: Rami Komrokji
  • Oral HMAs/pevonedistat in MDS: Guillermo Garcia-Manero

End Day 2, Conclusion & Wrap up

Friday 30th April 2021

10:00am EST Welcome and Introductions

10:00-10:50 Session 10: Mechanisms of drug resistance | Chairs: Jessica Altman & Andrew Wei

  • FLT3 inhibitors: Catherine Smith
  • Venetoclax: Andrew Wei
  • IDHi: Amir Fathi
  • GO: Roland Walter

Panel Discussion

10:50-11:40 Session 11: To target or not in elderly AML | Chairs: Mark Levis & Farhad Ravandi

Should FLT3 inhibitors be used in all frontline FLT3 AML not eligible for intensive therapy?

  • Pro: Naval Daver
  • Con: Alexander Perl

Panel Discussion

Is HMA-VEN or HMA-IDH inhibitor the optimal frontline therapy for frontline IDHm AML not eligible for intensive therapy?

  • Pro HMA-IDH: Eytan Stein
  • Pro HMA-VEN: Courtney DiNardo

Panel Discussion

11:40-12:30 Session 12: Emerging therapies in AML | Chairs: Gail Roboz & Courtney DiNardo

  • Molecular biomarkers and triplets with HMA-VEN: Marina Konopleva
  • Anti-CD47: David Sallman
  • Menin: Eunice Wang
  • RAR: Stephane de Botton
  • Oral HMA: Gail Roboz

Panel Discussion

12:30-13:30 Session 13: Immunotherapeutics in AML | Chairs: Naval Daver & Amir Fathi

  • Understanding immunobiology of AML: Ivana Gojo
  • BiTEs: Marion Subklewe
  • Checkpoints: Joshua Zeidner
  • CAR-T: Saar Gill

Panel Discussion

End Day 3, Conclusion & Wrap up

ENDS

Apply for registration for iwAL here

This event is for hematologists, researchers, nurses, and allied medical professionals only. Please apply for registration by filling in the form and confirming your details. We will review your application and confirm your registration on submission. By applying, you confirm that your details are correct and that the organizer can communicate with you regarding this event.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter